Researchers Develop Virus-Free and Oncogene-Free Induced Pluripotent Stem Cell Reprogramming

Biospace.com | January 29, 2019

Researchers with Iowa-based Cellular Engineering Technologies (CET), the John Paul II Medical Research Institute (JP2MRI) and the University of Iowa published research in late 2018 describing a safer and ethical method of creating pluripotent stem cells from cord blood and peripheral blood. It was published in the November 29 issue of the journal Regenerative Medicine. Pluripotent stem cells are master cells, which can create other cells or tissues that the body might need. All stem cells, pluripotent included, can self-renew and create more copies of themselves. There are several types of pluripotent stem cells, including embryonic stem cells. Embryonic stem cells originate from embryos. Most of these are derived from embryos that develop from eggs fertilized via in vitro. Which is at least partly where the John Paul II Medical Research Institute comes in, with the Catholic church’s opposition to embryonic stem cell research that involves the destruction of human embryos. JP2MRI is a non-profit medical research organization also based in Coralville, Iowa that follows the Catholic Church’s guidelines for ethical medical research.
Although most pluripotent stem cells are derived from human embryos that are only a couple days old, others have been developed from fetal tissue older than eight weeks. In 2007, the U.S. National Institutes of Health (NIH) notes, “scientists identified conditions that would allow some specialized adult human cells to be reprogrammed genetically to assume a stem cell-like state. These stem cells are called induced pluripotent stem cells (iPSCs). IPSCs are adult cells that have been genetically reprogrammed to an embryonic stem cell-like state by being forced to express genes and factors important for maintaining the defining properties of embryonic stem cells.”

Spotlight

This infographic related to the molecular biotechnology.
in which explained DNA process.

Spotlight

This infographic related to the molecular biotechnology.
in which explained DNA process.

Related News

MEDICAL

Felix Biotechnology Announces Initiation of CYPHY Phase 1/2 study at Yale for Lead Asset

Felix Biotechnology | January 08, 2021

Felix Biotechnology reported the inception of CYPHY, a Phase 1/2 examiner started single focus preliminary at Yale University for focused phage treatment YPT-01 in the therapy of constant P. aeruginosa diseases in cystic fibrosis. This twofold visually impaired, fake treatment controlled study (NCT 04684641) will evaluate the wellbeing and adequacy of YPT-01 added to standard antimicrobial treatment in 36 patients. CYPHY will likewise evaluate the capacity of YPT-01 to lessen the harmfulness and anti-infection obstruction of P. aeruginosa, improving patient results and re-empowering utilization of conventional anti-infection agents against multi-drug safe strains. The lead specialist for this investigation, Dr. Jon Koff, Associate Professor and Director of Yale's Adult Cystic Fibrosis Program, is supported by an academic grant from the Cystic Fibrosis Foundation. "This is a fantastic opportunity to show how effective phage therapy can be when deployed in an evolutionary framework. We know that pathogens evolve resistance to any antibiotic or therapy we use, so our approach turns that to our advantage," said Dr. Paul Turner, Professor of Ecology and Evolutionary Biology, co-inventor of YPT-01, and co-founder of Felix Biotechnology. "By targeting phage to mechanisms of virulence, we ensure that if pathogens evolve resistance to phage, they lose traits that make them effective pathogens, putting them in an evolutionary Catch-22."

Read More

CELL AND GENE THERAPY

Terumo Blood and Cell Technologies to Collaborate with CSL Plasma on U.S. FDA Clearance of Plasma Collection Technology

CSL Plasma | March 11, 2022

CSL Plasma, a division of global biotherapeutics pioneer CSL Behring, announced the Rika Plasma Donation System created by Terumo Blood and Cell Technologies, a medical technology company based in Lakewood, Colorado, has received regulatory approval. The new plasmapheresis system is expected to provide technologies to support a safe, efficient, and better experience for plasma donors and an improved experience for CSL Plasma personnel, according to Terumo Blood and Cell Technologies. Additional characteristics of the new Rika system, according to CSL Plasma, will allow for the collection of more plasma in less time, hence improving quality and safety and, in turn, better serving patients who rely on plasma-based therapies. These advantages include: On average, Rika completes one plasma collection in 35 minutes or less: Compared to previous average CSL Plasma donation timings, this might mean a nearly 30% reduction in donor donation time. It assures that no more than 200 milliliters of blood are ever removed from the donor's body. This is believed to make the donor more comfortable during the donation process and lessen the risk of red cell loss deferral. It has a sophisticated user interface that helps CSL Plasma front-line personnel operate the equipment. This milestone helps bring to life how we demonstrate innovation, collaboration, and patient-focus, part of the CSL Values that underpin our commitment to manufacturing and delivering life-saving and life-extending medicines around the world, We continue to evolve as a leading biotechnology company, investing in our core plasma business. Continued innovation that benefits our employees and plasma donors speak to how we are driven by our promise to save and improve lives around the world." CSL Chief Operating Officer Paul McKenzie. CSL Plasma will begin installing the new technology at locations in the Denver, Colorado, area in the following months. There is a critical and ongoing need for human plasma to produce life-saving medicines for people with serious and rare diseases, CSL Plasma's decision to work with Terumo Blood and Cell Technologies is consistent with our business goals to improve the donor and employee experience through innovation and remain the plasma donation center of choice. We look forward to rolling out this new technology." CSL Plasma General Manager Michelle Meyer.

Read More

AI

Charles River and Valence Discovery Declare Strategic Partnership to Provide AI-Enabled Drug Design Capabilities to Clients

Valence Discovery, Charles River | April 08, 2021

Charles River Laboratories International, Inc. and Valence Discovery today reported the arrangement of an essential association to give customers admittance to Valence's computerized reasoning stage for sub-atomic property expectation, generative science, and multiparameter improvement. Expanding on research done by Valence's establishing group at Mila, the world's biggest profound learning research organization, the Valence stage empowers the plan of little atom drug up-and-comers in novel districts of compound space, trailed by quick streamlining against project-explicit strength, selectivity, security, and pharmacology rules. Valence has spearheaded the utilization of few-shot learning in drug configuration, permitting the organization to open forecast errands for which just modest quantities of preparing information are accessible, defeating a basic constraint of existing AI advances in drug revelation. Banding together to Accelerate Discoveries By consolidating top tier AI advances with Charles River's start to finish abilities, the coalition can possibly essentially speed up revelation endeavors from hit plan through lead improvement. Through the cooperation, Charles River customers will have the alternative to get to Valence's foundation to help their medication revelation endeavors. When exploiting this alternative, customers can expect expanded variety in substance matter being examined, in mix with more fast improvement against complex, project-explicit plan measures, at last diminishing courses of events and improving achievement rates for drug revelation projects. Affirmed Quotes "This coordinated effort reflects Charles River's continuous obligation to improving our arrangement of creative innovation arrangements. We anticipate utilizing Valence's exceptional stage to improve results for our customers." – Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services, Charles River "The Valence stage offers a stage change improvement over existing again plan advancements. We've been reliably intrigued by Valence Discovery's capacity to create top notch synthetic matter that is promptly synthesizable, in novel areas of compound space, from datasets not in any case open to AI strategies." – Grant Wishart, PhD, Director of Computer Aided Drug Design, Charles River "We are excited to collaborate with Charles River, a worldwide pioneer trusted by numerous individuals of the world's top drug and biotech organizations. This cooperation is a significant advance in facilitating our central goal of engaging each medication disclosure researcher with the most recent developments in AI-empowered medication plan."– Daniel Cohen, CEO of Valence Discovery About Valence's AI-Enabled Drug Design Platform The Valence stage develops the scholarly community driving exploration done by the organization's establishing group at Mila, the world's biggest profound learning research foundation. Specifically, Valence has spearheaded the use of not many shot learning in drug configuration, permitting the organization to open forecast assignments for which just limited quantities of preparing information are accessible, including novel targets and complex ADME models, while additionally guaranteeing that AI-produced particles are of high therapeutic science quality and promptly synthesizable. Also, Valence utilizes dynamic learning and iterative improvement procedures to guarantee that lone the most data rich mixtures are chosen for amalgamation, empowering the plan of mixtures meeting the objective strength, selectivity, and ADME models in less emphasess, and with undeniably less information, than in any case conceivable. About Valence Discovery Valence is focused on opening the genuine capability of profound learning in drug plan by binding together top tier profound learning innovations with instinctive foundation to make these advances all the more extensively open to R&D associations, everything being equal. Valence's AI-empowered medication plan stage has been widely approved and is right now being utilized to distinguish and configuration drug applicants as a team with industry-driving accomplices. The organization is spearheading the utilization of few-shot learning in drug plan and is creating and conveying novel AI strategies for sub-atomic property expectation, generative science, and multiparameter advancement. Valence (once in the past InVivo AI) was established in 2018, is exhorted by profound learning pioneer, Dr. Yoshua Bengio, and is gladly settled in Montreal at Mila, the world's biggest profound learning research foundation, with an office in Cambridge, Mass. About Charles River Charles River gives fundamental items and administrations to help drug and biotechnology organizations, government offices and driving scholastic foundations all throughout the planet speed up their exploration and medication improvement endeavors. Our devoted workers are centered around giving customers precisely what they need to improve and assist the disclosure, beginning phase advancement and safe production of new treatments for the patients who need them.

Read More